Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Total Valuation
Ionis Pharmaceuticals has a market cap or net worth of $4.44B. The enterprise value is $5.18B.
Market Cap$4.44B
Enterprise Value$5.18B
Share Statistics
Ionis Pharmaceuticals has 158.96M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding158.96M
Owned by Insiders0.74%
Owned by Instutions0.23%
Financial Efficiency
Ionis Pharmaceuticals’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -17.40%.
Return on Equity (ROE)-77.15%
Return on Assets (ROA)-15.11%
Return on Invested Capital (ROIC)-17.40%
Return on Capital Employed (ROCE)-17.63%
Revenue Per Employee$659,797.007
Profits Per Employee-$424,599.626
Employee Count1,069
Asset Turnover0.23
Inventory Turnover0.90
Valuation Ratios
The current PE Ratio of Ionis Pharmaceuticals is -11.52. Ionis Pharmaceuticals’s PEG ratio is -0.61.
PE Ratio-11.52
PS Ratio7.41
PB Ratio8.88
Price to Fair Value8.88
Price to FCF-9.57
Price to Operating Cash Flow-10.43
PEG Ratio-0.61
Income Statement
In the last 12 months, Ionis Pharmaceuticals had revenue of $705.32M and earned -$453.90M in profits. Earnings per share was -$3.08.
Revenue$705.32M
Gross Profit$682.88M
Operating Income-$475.08M
Pretax Income-$460.07M
Net Income-$453.90M
EBITDA-358.31M
Earnings Per Share (EPS)-3.08
Cash Flow
In the last 12 months, operating cash flow was -$500.95M and capital expenditures -$47.83M, giving a free cash flow of -$551.29M billion.
Operating Cash Flow-$500.95M
Free Cash Flow-$551.29M
Free Cash Flow per Share-$3.47
Dividends & Yields
Ionis Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-10.45%
Earnings Yield-8.68%
Stock Price Statistics
Beta0.77
52-Week Price Change-32.85%
50-Day Moving Average31.45
200-Day Moving Average38.62
Relative Strength Index (RSI)42.27
Average Volume (3m)1.83M
Important Dates
Ionis Pharmaceuticals upcoming earnings date is Apr 30, 2025, Before Open.
Last Earnings DateFeb 19, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend Date―
Financial Position
Ionis Pharmaceuticals as a current ratio of 8.47, with Debt / Equity ratio of 2.39
Current Ratio8.47
Quick Ratio8.43
Debt to Market Cap0.27
Net Debt to EBITDA-2.45
Interest Coverage Ratio-5.63
Taxes
In the past 12 months, Ionis Pharmaceuticals has paid -$6.55M in taxes.
Income Tax-$6.55M
Effective Tax Rate1.34%
Enterprise Valuation
Ionis Pharmaceuticals EV to EBITDA ratio is -13.46, with an EV/FCF ratio of -11.70.
EV to Sales9.07
EV to EBITDA-13.46
EV to Free Cash Flow-11.70
EV to Operating Cash Flow-12.76
Balance Sheet
Ionis Pharmaceuticals has $2.30B in cash and marketable securities with $1.42B in debt, giving a net cash position of -$881.09M billion.
Cash & Marketable Securities$2.30B
Total Debt$1.42B
Net Cash-$881.09M
Net Cash Per Share-$5.54
Tangible Book Value Per Share$3.94
Margins
Gross margin is 98.41%, with operating margin of -67.37%, and net profit margin of -64.37%.
Gross Margin98.41%
Operating Margin-67.37%
Pretax Margin-65.25%
Net Profit Margin-64.37%
EBITDA Margin-67.37%
EBIT Margin-67.66%
Analyst Forecast
The average price target for Ionis Pharmaceuticals is $55.47, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$55.47
Price Target Upside98.82%
Analyst ConsensusModerate Buy
Analyst Count20
Revenue Growth Forecast-10.48%
EPS Growth Forecast-18.79%